



**UVEITIS
NATIONAL
CLINICAL
STUDY
GROUP**

NEWSLETTER

Special Edition · August 2026
www.uveitisstudygroup.org

SPECIAL EDITION

National Pathways in Ocular Inflammatory Disease

Uveitis CSG Delphi Consensus Project

IN THIS ISSUE

- › What the project is, and why now
- › A shared standard across the four nations
- › How the consensus will work
- › How to get involved — and your regional representatives

FROM THE UVEITIS CSG

Welcome — and thank you for joining

Thank you to all the consultants and pharmacists who attended our Informational Meeting on 22 July 2026 — it was a very encouraging start.

Thank you for joining this project. We warmly welcome your support and collaboration. Our aim is to develop a common, consensus-led set of clinical pathways for the biologic management of ocular inflammatory disease — and to publish them as a UK-wide reference standard of best practice, spanning, in time, both children and adults.

In this edition, we explain what the project is, share some information about it, and set out how you can take part in the national consensus.

OUR AIM

A common, consensus-led set of biologic pathways for ocular inflammatory disease — published as a UK-wide reference standard of best practice, in time spanning both children and adults.

NEAR-TERM GOALS

Why now

In the near term this will help England-based clinicians access biologic therapies more consistently by leveraging existing UK access routes and lay the groundwork for NHS England-commissioned pathways — the first being tocilizumab for refractory non-infectious uveitis.

SCOPE

A shared standard across the four nations

Commissioning differs across the four nations, so this is intended as a shared clinical standard that each nation can adopt through its own route. Contributions from all four nations will make the consensus stronger and more widely useful.

Detailed information — how commissioning differs across the four nations, what is changing in English commissioning, and how to make use of it — is set out in a companion document on our website: [Introduction to Commissioning and National Pathways for Treatment in Ocular Inflammatory Diseases](#).

THE DELPHI PROCESS

How the consensus will work

We will use a structured, Delphi-style process so that every contributor has an equal voice:

1. An informational meeting to introduce the evidence and the draft pathways.
2. A structured survey in which you rate each proposed statement.
3. Collation of responses, with a moderated discussion of any items that do not reach agreement.

Where the evidence is strong we will follow it; on matters of collective clinical practice we aim to carry the majority rather than impose a view, and we will record where views differ — so a degree of regional variation is expected and respected. *[Editable: add consensus threshold, quorum and the meeting dates for this edition.]*

NEXT STEPS

How to get involved

We would welcome your involvement, however much time you have.

- Consultants, specialty doctors and pharmacists can email us directly.

Email: info@uveitisstudygroup.org

- If you are in England, you can instead send a quick expression of interest to your regional representative.

REGIONAL REPRESENTATIVES

North West Eleftherios Agorogiannis	North East Helen Devonport
Midlands Sreekanth Sreekantham & Balini Balasubramaniam	South West Simon Epps
London Trusts Will Tucker	South Coast / Kent <i>to be confirmed</i>
Scotland <i>to be confirmed</i>	Northern Ireland <i>to be confirmed</i>
Wales <i>to be confirmed</i>	

Look out, too, for the meeting invitation and the survey link, which are sent separately.

On our website you will also find a companion introduction — to commissioning for England, to this project, and to getting started with biologics in your area: [Introduction to Commissioning and National Pathways for Treatment in Ocular Inflammatory Diseases](#).

With warm wishes and thanks for your support,

The Uveitis Clinical Study Group

www.uveitisstudygroup.org · info@uveitisstudygroup.org

Special edition of the Uveitis CSG newsletter, dedicated to the National Pathways in Ocular Inflammatory Disease Delphi Consensus Project. For information and discussion among the CSG network. © 2026 Uveitis National Clinical Study Group.